Table 3.
Comparison of post PK endophthalmitis studies.
| Leveille1 | Guss2 | Pardos3 | Kloess4 | Taban5 | Henry6 | Chen7 | Kunimoto10 | Antonios11 | Cameron12 | Alharbi13 | Cameron14 | Keyhani15 | Edelstein17 | Hassan18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year of publication | 1983 | 1983 | 1982 | 1993 | 2005 | 2013 | 2015 | 2004 | 1991 | 1991 | 2014 | 1998 | 2005 | 2016 | 2005 |
| Country | USA | USA | USA | USA | ◊ | USA | UK | USA | Saudi Arabia | Saudi Arabia | Saudi Arabia | Saudi Arabia | USA | USA | USA |
| Number of PKs | 1876 | 445 | 1880 | 1010 | 90549◊◊ | – | 11320 | – | 2210 | 3000 | 6752 | 16 | 2466 | 195859 | – |
| Number of reported endophthalmitis cases | 4 | 11 | 2 | 4 | – | 5 | 76 | 14 | 9 | 10 | 55° | 4 | 3 | 37 | 234 |
| Reported incidence of endophthalmitis | 0.21% | 2.47% | 0.1% | 0.40% | 0.38%◊◊ | – | 0.67%● | – | 0.41% | 0.33% | 0.68% | – | 0.12% | 0.018% | – |
| Number of culture positive endophthalmitis cases | 4/4 | 10/11 | 1/2 | 4/4 | – | 5/5 | 13/24●● | 13/14 | 9/9 | 6/10♠ | 49/55° | 4/4 | 3/3 | 77/99¥ | 176/234 |
| Etiology | |||||||||||||||
| Suture related complication | – | 0/11 | 0/2 | – | – | 5/5 | – | – | – | 0/6 | 19/55° | 0/4 | 0/3 | – | – |
| Wound leak/dehiscence | – | 0/11 | 0/2 | 4/4 | – | 0/5 | – | – | – | 0/6 | 4/55° | 0/4 | 0/3 | – | – |
| Keratitis | – | 6/11 | 0/2 | 1/4 | – | 5/5 | – | – | – | 1/6 | 47/55° | 0/4 | 0/3 | – | – |
| Contaminated donor | 3/4 | 0/11 | 1/2 | 3/4 | – | 0/5 | – | – | 5/9 | 6/6 | – | 4/4 | 3/3 | – | – |
| Other | 1/4 | 5/11 | 0/2 | – | – | 0/5 | – | – | – | 0/6 | – | 0/4 | 1/3 | – | – |
| Isolate | |||||||||||||||
| Gram positive | 3/4 | 8/10 | 0/1 | 2/4 | – | 5/5 | 9/13●●● | 10/13 | 6/9 | 2/6 | 68/80°° | 3/4 | 0/3 | 27/82¥¥ | 130/176ǁ |
| Gram negative | 1/4 | 1/10 | 1/1 | 0/4 | – | – | 9/13●●● | 3/13 | 0/9 | 1/6 | 10/80°° | 0/4 | 0/3 | 2/82¥¥ | 130/176ǁ |
| Fungal | 0/4 | 1/10 | 0/1 | 2/4 | – | – | 4/13 | 0/13 | 3/0 | 3/6 | 2/80°° | 1/4 | 3/3 | 53/82¥¥ | 46/176 |
| Primary management | |||||||||||||||
| Intravitreal antimicrobials | 1/4 | 4/11 | 0/2 | 1/4 | – | 4/5 | – | – | ? | 6/6 | 38/53°°° | 2/4ǂ | – | – | – |
| PPV | 2/4 | 7/11 | 2/2 | 3/4 | – | 2/5 | – | – | ? | 0/6 | 13/53°°° | 0/4 | – | – | – |
| Evisceration | 1/4 | 0/11 | 0/2 | 0/4 | – | – | – | 0/6 | 15/53°°° | 0/4 | – | – | – | ||
| Last VA | |||||||||||||||
| < 5/200 | 2/4 | 9/11 | 2/2 | 4/4 | – | 3/5 | – | – | ? | 3/6 | 48/55° | 2/4 | – | – | – |
| ≥ 5/200 (better) | 2/4 | 2/11 | 0/2 | 0/4 | – | 2/5 | – | – | ? | 3/6 | 7/55° | 2/4 | – | – | – |